Also, in terms of first-in-class drugs, one of you mentioned that you're not providing a barrier to new drugs and therapies, as some have maintained. Those concerns were put forward at various times along the way in our testimony. The impression I was getting was that it's a very low level of first-in-class drugs being recommended for listing.
Is that inaccurate information, then, that some have suggested to us?